Cachexia is a major cause of weight loss and increased mortality that affects more than five million people in the U.S. Clinically, cachexia manifests with excessive weight loss in the setting of ongoing disease, usually with disproportionate muscle wasting. Differentiation from other syndromes of weight loss is pivotal to prompt recognition and effective management of cachexia. Weight loss resulting from the syndrome of starvation occurs as a direct result of caloric deprivation. Starved persons generally lose more fat than muscle tissue. The underlying pathophysiologic mechanisms of cachexia are unclear. Cachexia is a common problem in people with severe diseases and is highly predictive of increased mortality. Cachexia also contributes to the decline in quality of life that accompanies end-stage disease. Nonetheless, emerging evidence suggests that cytokines play a central role in the pathogenesis of cachexia. Nutritional support alone may be inadequate in the management of cachexia. There is an emerging role for orexigenic agents in the management of cachexia. The drug candidates of cachexia pipeline include, but are not limited to, Xilonix, Bimagrumab and Landogrozumab.
Some of the companies having drugs in the cachexia pipeline include Acacia Pharma Limited, Aphios Corporation, Atara Biotherapeutics, Inc., and Connexios Life Sciences Pvt. Ltd.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.